

05/01/01
jc961 U.S. PTO

WDN/SAS:gte 5/1/01 48856.doc
Attorney Reference Number 899-58137
PATENT

EXPRESS MAIL LABEL NO. EL828141138US
DATE OF DEPOSIT: May 1, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION
COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

jc962 U.S. PTO
09/847172
05/01/01

Transmitted herewith for filing is the continuing patent application of:

Inventor(s): Gregory G. Burrows and Arthur A. Vandembark

For: RECOMBINANT MHC MOLECULES USEFUL FOR MANIPULATION OF
ANTIGEN-SPECIFIC T-CELLS

Enclosed are:

- ☒ 105 pages of specification, 9 pages of claims, and an abstract
☒ 28 sheet(s) of drawings.
☒ 3 pages of an Oath or Declaration (UNSIGNED)
☐ newly executed (original or copy)
☐ A copy of oath or declaration filed with the prior application (37 C.F.R. § 1.63(d))
☐ The inventors to be deleted are set forth on a separate sheet attached hereto.
- ☒ Request for Non-publication and Certification under 35 U.S.C. § 122(b)(2)(B)(i).

Continuing Application:

- ☐ Continuation
☐ Divisional
☒ Continuation-in-part (CIP)

Information from Prior Application:

Prior Application Number: 09/153,586
Examiner: Amy DeCloux, Ph.D.
Art Unit: 1644

☒ Priority Claim:

This application is a continuation-in-part of co-pending U.S. Patent Application No. 09/153,586, filed September 15, 1998, which claims priority to U.S. Provisional Patent Application No. 60/064,552, filed September 16, 1997, and U.S. Provisional Patent Application No. 60/064,555, filed October 10, 1997, all of which are incorporated herein by reference. This application also claims priority to U.S. Provisional Patent Application No. 60/200,942, filed May 1, 2000.

FILING FEE					
For	Claims Filed	Number Allotted	Number Extra	Rate	Basic Fee
Total Claims	58	20	= 38	\$9.00	\$ 342.00
Independent Claims	10	3	= 7	\$40.00	\$ 280.00
Multiple Dependent Claim Fee				\$135.00	\$0.00
TOTAL FILING FEE					\$977.00

Small entity status is claimed for this application.

- ☒ A check in the amount of \$977.00 to cover ☒ filing fee and ☐ assignment recordal fee is enclosed.
- ☒ The entire disclosure of parent application 09/153,586 is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference herein.
- ☒ The Director is hereby authorized to charge any additional fees which may be required in connection with the filing of this application and recording any assignment filed herewith, or credit over-payment, to Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN CAMPBELL
LEIGH & WHINSTON, LLP

By William D. Noonan
William D. Noonan, M.D.
Registration No. 30,878

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing Secretary

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Burrows et al.

For: RECOMBINANT MHC MOLECULES USEFUL FOR MANIPULATION OF ANTIGEN-SPECIFIC T-CELLS

Examiner: To be assigned

Date: May 1, 2001

Art Unit: To be assigned

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

**REQUEST FOR NON-PUBLICATION AND CERTIFICATION UNDER
35 U.S.C. § 122(b)(2)(B)(i)**

Applicant may rescind this nonpublication request at any time. See "Request to Rescind Previous Nonpublication Request". If applicant rescinds a request that an application not be published under 35 U.S.C. § 122(b), the application will be scheduled for publication at eighteen months from the earliest claimed filing date for which a benefit is claimed.

If applicant subsequently files an application directed to the invention disclosed in the attached application in another country, or under a multilateral international agreement, that requires publication of applications eighteen months after filing, applicant must notify the United States Patent and Trademark Office of such filing within forty-five (45) days after the date of the filing of such foreign or international application. Failure to do so will result in abandonment of this application (35 U.S.C. § 122 (b)(2)(B)(iii)).

This request is signed in compliance with 37 CFR § 1.33(b) and is submitted with the application upon filing. I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. § 122(b).

Dated: May 1, 2001

Respectfully submitted,

KLARQUIST SPARKMAN CAMPBELL
LEIGH & WHINSTON, LLP

By William D. Noonan
William D. Noonan, M.D.
Registration No. 30,878

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446